Decline in Japanese Encephalitis, Kushinagar District, Uttar Pradesh, India

To the Editor: Kakkar et al. recently concluded that the low-quality surveillance data on acute encephalitis syndrome (AES)/Japanese encephalitis (JE) in Kushinagar District, India, provide little evidence to support development of prevention and control measures and to estimate the effect of interventions (1). Analysis of the surveillance data, however, does provide evidence supporting the effect of an ongoing intervention (i.e., JE vaccination). 
 
In accordance with the surveillance protocol, cerebrospinal fluid and/or serum samples from AES patients admitted to the Baba Raghav Das Medical College (Gorakhpur, India) are tested for IgM against JE at the field laboratory of National Institute of Virology (NIV) at Gorakhpur (2). The samples are tested by using the ELISA developed by NIV Pune (Pune, India), which has a specificity of 85% (range 77%–95%) and sensitivity of 71% (range 71%–75%) (3). Patients with samples negative for JE are considered to have JE-negative AES. 
 
We obtained the line-list of AES patients from the NIV laboratory at Gorakhpur for 2008–2012. Analysis of the surveillance data indicated that 251 (8.2%, range 4%–14.7%) of the 3,047 AES patients from Kushinagar were positive for JE IgM and therefore considered to be JE case-patients. JE incidence per 100,000 persons in the district declined from 2.3 cases in 2010 to 0.81 in 2011 to 0.58 in 2012 (Figure). The decline in JE incidence since 2010 could be a consequence of JE vaccination activities in Kushinagar. In 2010, a mass vaccination campaign with 1 dose of JE vaccine (SA 14–14–2 strain) was conducted among children 1–15 years of age. Subsequently, the vaccine was introduced into the childhood vaccination program as a 1-dose strategy in 2011 and a 2-dose strategy in 2013. Unfortunately, information about evaluated coverage of JE vaccine is not available from the district. On the other hand, the average annual incidence of JE-negative AES during the same period was 16 cases per 100,000 persons (95% CI 14.8–17.2), and this incidence has remained relatively stable since 2008. 
 
 
 
Figure 
 
Annual incidence of Japanese encephalitis (JE) and JE-negative acute encephalitis syndrome (AES), Kushinagar District, Uttar Pradesh, India, 2008–2012. 
 
 
 
With the isolation of enteroviruses from JE-negative AES patients, waterborne transmission has been hypothesized, and the focus of intervention has shifted toward improving sanitation and water quality. However, enteroviruses were detected only in a small proportion of AES patients. Although the quality of AES surveillance needs to be improved, as Kakkar et al. suggested (1), further studies are needed to understand the etiology of JE-negative AES in the district and the risk factors for transmission. These studies might include systematically investigating patients and environmental samples for enteroviral and other etiologic agents.

To the Editor: Kakkar et al. recently concluded that the low-quality surveillance data on acute encephalitis syndrome (AES)/Japanese encephalitis (JE) in Kushinagar District, India, provide little evidence to support development of prevention and control measures and to estimate the effect of interventions (1). Analysis of the surveillance data, however, does provide evidence supporting the effect of an ongoing intervention (i.e., JE vaccination).
In accordance with the surveillance protocol, cerebrospinal fluid and/or serum samples from AES patients admitted to the Baba Raghav Das Medical College (Gorakhpur, India) are tested for IgM against JE at the field laboratory of National Institute of Virology (NIV) at Gorakhpur (2). The samples are tested by using the ELISA developed by NIV Pune (Pune, India), which has a specificity of 85% (range 77%-95%) and sensitivity of 71% (range 71%-75%) (3). Patients with samples negative for JE are considered to have JE-negative AES.
We obtained the line-list of AES patients from the NIV laboratory at Gorakhpur for 2008-2012. Analysis of the surveillance data indicated that 251 (8.2%, range 4%-14.7%) of the 3,047 AES patients from Kushinagar were positive for JE IgM and therefore considered to be JE case-patients. JE incidence per 100,000 persons in the district declined from 2.3 cases in 2010 to 0.81 in 2011 to 0.58 in 2012 (Figure). The decline in JE incidence since 2010 could be a consequence of JE vaccination activities in Kushinagar. In 2010, a mass vaccination campaign with 1 dose of JE vaccine (SA 14-14-2 strain) was conducted among children 1-15 years of age. Subsequently, the vaccine was introduced into the childhood vaccination program as a 1-dose strategy in 2011 and a 2-dose strategy in 2013. Unfortunately, information about evaluated coverage of JE vaccine is not available from the district. On the other hand, the average annual incidence of JE-negative AES during the same period was 16 cases per 100,000 persons (95% CI 14.8-17.2), and this incidence has remained relatively stable since 2008.
With the isolation of enteroviruses from JE-negative AES patients, waterborne transmission has been hypothesized, and the focus of intervention has shifted toward improving sanitation and water quality. However, enteroviruses were detected only in a small proportion of AES patients. Although the quality of AES surveillance needs to be improved, as Kakkar et al. suggested (1), further studies are needed to understand the etiology of JE-negative AES in the district and the risk factors for transmission. These studies might include systematically investigating patients and environmental samples for enteroviral and other etiologic agents.

2006-2011
To the Editor: Since zoonotic babesiosis was first identified in the United States in 1966 (1), its incidence and geographic range have increased (2). Previous studies have demonstrated increases in transfusion-associated cases in recent years (3). In 2011, babesiosis became nationally notifiable as its emergence and the potential for transfusion-associated cases were recognized (2,4). We assessed New Jersey, USA, surveillance data for 2006-2011 to characterize case information (incidence, potential transfusion associations, geographic distribution) in a state where babesiosis is endemic.
In New Jersey, babesiosis case reporting began in 1985. A retrospective study identified an upward trend during 1993-2001; eight of 21 counties reported cases (5). In 2005, the New Jersey Department of Health